AACR 2019 | ECS progastrin | Atlanta

ECS progastrin SA is a subsidiary of

Progastrine Invest SCSp – Cancer Control Funding Fund

11 côte d'Eich, L1450,

Luxembourg City - Grand Duchy of Luxembourg

Progastrine invest

11 côte d'Eich,

L1450 Luxembourg ville

Grand Duché du Luxembourg

ECS progastrin Lab

Chemin de la Meunière 12

Prilly 1008

Suisse

Progastrin Manufacturing

Chemin de la Meunière 12

Prilly 1008

Suisse

Progastrine et cancers

11 côte d'Eich,

L1450 Luxembourg ville

Grand Duché du Luxembourg

Eurobiodev

2040 avenue du Père Soulas

34000 Montpellier

France

Progastrine Invest SCSp and its subsidiaries

  • focus on innovation in cancer screening, diagnosis and treatment,

  • hold the rights to the first circulating progastrin assay, identified as a new marker associated with cancer. This dosage helps to screen for cancer even at early stages and to monitor therapies,

  • are the holders of the rights to the cancer therapy project with an anti-progastrin antibody.

 

For ethical reasons and out of respect for practitioners, health institutions, populations and regulations in force in all countries where they operate, Progastrine Invest SCSp and its subsidiaries pay extreme attention to the information they publicly provide.

 

The management of Progastrine Invest SCSp, its subsidiaries and their scientific committee would like to remind you that only information published on the official communication media of the group's companies can be considered as confirmed and authorised.

© 2018 ECS progastrin

logo ECS progastrine_noir-rouge.jpg

Contact us

ECS progastrin's boot #4360

AACR annual meeting- Atlanta

March 29th > April 3rd 2019

To set up an appointment with our scientists
during the AACR annual congress
from 29th March to 3rd April 2019
Please fill in the form below
or call us on +1 (562) 725 6711:

We invite you also to meet our experts at the POSTERS SESSIONS:

 

Dear AACR 2019 Participant,

The work of many researchers around the world has demonstrated[1] the strong link between progastrin and cancer. (see Progastrin White Paper)

These observations have been extended by showing today the multiple possibilities that circulating progastrin offers in helping to detect and diagnose cancer, in supporting therapeutic follow-upin monitoring relapses or in treating cancer itself, alone or in combination with other therapeutic means.

In partnership with Mayo Clinic Rochester and Montpellier University Hospital, our Swiss company ECS Progastrin will present 3 posters at the AACR2019 which will provide you with information on the interest of targeting progastrin in the blood during the follow-up of treatments (prostate, kidney and liver) to bring more decision-making elements to physicians.

Mrs. Dominique Joubert PhD, the pioneer of our progastrin project, together with Mr. Alexandre Prieur PhD, CSO, will be both present at the AACR annual meeting 2019 with the team, in order to introduce you to this new biomarker and our clinical developments on 15 types of cancer (including cancers for which there is no known biomarker).

 

Our IVD test, DxPG80.Lab, is based on the detection of circulating progastrin which is specifically released in blood by tumor cells during the early stages of cancer and throughout its course. It is currently marketed under an RUO label in the USA and a CE-IVD label elsewhere.

Moreover, it has been shown that progastrin is essential for the survival of tumor stem cells and that its neutralization leads to "Tumor Reversion": The tumor cell becomes "normal-like", differentiates and dies (Prieur et al., 2017)[2]. These observations will give rise to a new therapy that targets cancer stem cells, and which is under development.

Progastrin,

a new revolutionary biomarker to help fight cancer?
We are sure you will be convinced!
 

 

We look forward to speaking with you at AACR 2019.

The ECS Progastrin team.

 

 

ECS Progastrin Lab
Chemin de la Meunière 12,
Prilly (Lausanne), Vaud 1008, 
SWITZERLAND

www.ecs-progastrin.com 

contact@ecs-progastrin.com

 

[1]: White Paper"Progastrin and its link to cancer : From the discovery of progastrin to tumor reversion" [Progastrin-Cancer-Control Association – FR] 2018. (download here

 

 

[2]: Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer– DOI:10.1158/1078-0432.CCR-17-0533 Published September 2017. Alexandre Prieur, Monica Cappellini, Guillaume Habif, Marie-Paule Lefranc, Thibault Mazard, Eric Morency, Jean-Marc Pascussi, Maud Flacelière, Nathalie Cahuzac, Bérengère Vire, Benjamin Dubuc, Amandine Durochat, Pierre Liaud, Jérémy Ollier, Caroline Pfeiffer, Sophie Poupeau, Véronique Saywell, Chris Planque, Eric Assenat, Frédéric Bibeau, Jean-François Bourgaux, Pascal Pujol, Alain Sézeur, Marc Ychou and Dominique Joubert.

ECS progastrin

booth #4360

AACR2019

29TH March

> 03RD April

2019

In association with PROGASTRIN cancer control Association,

ECS progastrin is proud to present the Progastrin's WHITE PAPER 

Progastrin and its link to cancer:

from the discovery of progastrin   to tumor reversion  

by Dominique Joubert, PhD in biology

and Alexandre Prieur, PhD in oncology

click on this icon to download the document

Couv Progastrin White Paper.jpg
 

Secure your future